vs

Side-by-side financial comparison of Astrana Health, Inc. (ASTH) and Solstice Advanced Materials Inc. (SOLS). Click either name above to swap in a different company.

Solstice Advanced Materials Inc. is the larger business by last-quarter revenue ($969.0M vs $950.5M, roughly 1.0× Astrana Health, Inc.). Astrana Health, Inc. runs the higher net margin — 0.7% vs -3.6%, a 4.3% gap on every dollar of revenue. On growth, Astrana Health, Inc. posted the faster year-over-year revenue change (42.9% vs 6.8%). Solstice Advanced Materials Inc. produced more free cash flow last quarter ($41.0M vs $-6.0M).

Astrana Health, Inc. is a U.S.-based value-based healthcare services provider that primarily serves Medicare-eligible senior populations across the United States. It offers in-home primary care, chronic disease management, and care coordination services, aiming to improve patient health outcomes and reduce unnecessary medical costs.

Solstice Advanced Materials Inc. is a specialty advanced materials provider that develops, produces and distributes high-performance functional materials for renewable energy systems, consumer electronics, industrial manufacturing and advanced automotive sectors. The company focuses on material solutions that boost product durability, energy efficiency and operational performance for its global clients.

ASTH vs SOLS — Head-to-Head

Bigger by revenue
SOLS
SOLS
1.0× larger
SOLS
$969.0M
$950.5M
ASTH
Growing faster (revenue YoY)
ASTH
ASTH
+36.1% gap
ASTH
42.9%
6.8%
SOLS
Higher net margin
ASTH
ASTH
4.3% more per $
ASTH
0.7%
-3.6%
SOLS
More free cash flow
SOLS
SOLS
$47.0M more FCF
SOLS
$41.0M
$-6.0M
ASTH

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
ASTH
ASTH
SOLS
SOLS
Revenue
$950.5M
$969.0M
Net Profit
$6.6M
$-35.0M
Gross Margin
32.0%
Operating Margin
1.9%
17.9%
Net Margin
0.7%
-3.6%
Revenue YoY
42.9%
6.8%
Net Profit YoY
184.4%
-123.0%
EPS (diluted)
$0.12

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ASTH
ASTH
SOLS
SOLS
Q4 25
$950.5M
Q3 25
$956.0M
$969.0M
Q2 25
$654.8M
Q1 25
$620.4M
Q4 24
$665.2M
Q3 24
$478.7M
$907.0M
Q2 24
$486.3M
Q1 24
$404.4M
Net Profit
ASTH
ASTH
SOLS
SOLS
Q4 25
$6.6M
Q3 25
$373.0K
$-35.0M
Q2 25
$9.4M
Q1 25
$6.7M
Q4 24
$-7.8M
Q3 24
$16.1M
$152.0M
Q2 24
$19.2M
Q1 24
$14.8M
Gross Margin
ASTH
ASTH
SOLS
SOLS
Q4 25
Q3 25
32.0%
Q2 25
Q1 25
Q4 24
Q3 24
36.6%
Q2 24
Q1 24
Operating Margin
ASTH
ASTH
SOLS
SOLS
Q4 25
1.9%
Q3 25
2.0%
17.9%
Q2 25
3.1%
Q1 25
3.3%
Q4 24
0.1%
Q3 24
5.9%
21.7%
Q2 24
6.2%
Q1 24
7.5%
Net Margin
ASTH
ASTH
SOLS
SOLS
Q4 25
0.7%
Q3 25
0.0%
-3.6%
Q2 25
1.4%
Q1 25
1.1%
Q4 24
-1.2%
Q3 24
3.4%
16.8%
Q2 24
3.9%
Q1 24
3.7%
EPS (diluted)
ASTH
ASTH
SOLS
SOLS
Q4 25
$0.12
Q3 25
$0.01
Q2 25
$0.19
Q1 25
$0.14
Q4 24
$-0.14
Q3 24
$0.33
Q2 24
$0.40
Q1 24
$0.31

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ASTH
ASTH
SOLS
SOLS
Cash + ST InvestmentsLiquidity on hand
$429.5M
$417.0M
Total DebtLower is stronger
Stockholders' EquityBook value
$779.3M
$3.2B
Total Assets
$2.2B
$5.2B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ASTH
ASTH
SOLS
SOLS
Q4 25
$429.5M
Q3 25
$463.4M
$417.0M
Q2 25
$342.1M
Q1 25
$260.9M
Q4 24
$290.8M
Q3 24
$350.3M
Q2 24
$327.7M
Q1 24
$337.3M
Stockholders' Equity
ASTH
ASTH
SOLS
SOLS
Q4 25
$779.3M
Q3 25
$775.5M
$3.2B
Q2 25
$765.5M
Q1 25
$745.4M
Q4 24
$712.7M
Q3 24
$704.6M
$3.2B
Q2 24
$678.9M
Q1 24
$653.5M
Total Assets
ASTH
ASTH
SOLS
SOLS
Q4 25
$2.2B
Q3 25
$2.2B
$5.2B
Q2 25
$1.4B
Q1 25
$1.3B
Q4 24
$1.4B
Q3 24
$1.3B
Q2 24
$1.3B
Q1 24
$1.2B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ASTH
ASTH
SOLS
SOLS
Operating Cash FlowLast quarter
$-2.9M
$289.0M
Free Cash FlowOCF − Capex
$-6.0M
$41.0M
FCF MarginFCF / Revenue
-0.6%
4.2%
Capex IntensityCapex / Revenue
0.3%
25.6%
Cash ConversionOCF / Net Profit
-0.44×
TTM Free Cash FlowTrailing 4 quarters
$104.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ASTH
ASTH
SOLS
SOLS
Q4 25
$-2.9M
Q3 25
$10.0M
$289.0M
Q2 25
$90.9M
Q1 25
$16.6M
Q4 24
$-10.9M
Q3 24
$34.0M
Q2 24
$23.2M
Q1 24
$6.0M
Free Cash Flow
ASTH
ASTH
SOLS
SOLS
Q4 25
$-6.0M
Q3 25
$7.4M
$41.0M
Q2 25
$89.5M
Q1 25
$13.6M
Q4 24
$-13.5M
Q3 24
$31.7M
Q2 24
$20.4M
Q1 24
$5.6M
FCF Margin
ASTH
ASTH
SOLS
SOLS
Q4 25
-0.6%
Q3 25
0.8%
4.2%
Q2 25
13.7%
Q1 25
2.2%
Q4 24
-2.0%
Q3 24
6.6%
Q2 24
4.2%
Q1 24
1.4%
Capex Intensity
ASTH
ASTH
SOLS
SOLS
Q4 25
0.3%
Q3 25
0.3%
25.6%
Q2 25
0.2%
Q1 25
0.5%
Q4 24
0.4%
Q3 24
0.5%
Q2 24
0.6%
Q1 24
0.1%
Cash Conversion
ASTH
ASTH
SOLS
SOLS
Q4 25
-0.44×
Q3 25
26.69×
Q2 25
9.65×
Q1 25
2.48×
Q4 24
Q3 24
2.11×
Q2 24
1.21×
Q1 24
0.40×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ASTH
ASTH

Medicare$542.4M57%
Commercial$99.1M10%
Care Delivery$92.1M10%
Care Enablement$78.9M8%
Other Third Parties$58.0M6%
Health Care Patient Service$39.8M4%
Health Care Other$25.5M3%
Other$12.1M1%
Management Service$10.3M1%

SOLS
SOLS

Refrigerants$400.0M41%
Research And Performance Chemicals$126.0M13%
Electronic Materials$103.0M11%
Other$89.0M9%
Services$64.0M7%
Alternative Energy Services$63.0M7%
Safety And Defense Solutions$53.0M5%
Healthcare Packaging$49.0M5%
Affiliated Entity$22.0M2%

Related Comparisons